ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1054

Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review
Abstract Number: 2192

Utilizing Electronic Health Record Pre-Consultation Data to Create a Predictive Algorithm for Diagnosis of Chronic Pediatric Rheumatic Conditions
Abstract Number: 1526

Utilizing Electronic Health Records to Identify Clinical Features of ANA-Positive Patients Imparting High Risk for Progression to Systemic Lupus Erythematosus
Abstract Number: 1604

Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 0929

UVB-Induced Keratinocyte-Derived Extracellular Vesicles: Cytokeratin 10 as a Marker of Epidermal Origin
Abstract Number: 1461

Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center
Abstract Number: 2613

Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Abstract Number: 0977

Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Abstract Number: 0025

Vagus Nerve Stimulation: A Promising Approach to Alleviate Pain and Systemic Inflammation in Slow and Rapid Models of Osteoarthritis
Abstract Number: 1874

Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
Abstract Number: 2395

Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)
Abstract Number: 1588

Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy
Abstract Number: 1509

Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
Abstract Number: 0821

Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis
Abstract Number: 1970

Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis for Enthesitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].